Sorafenib Tosylate/ high quality/ CAS:475207-59-1

Shandong Fengjin Beauty Biotech is a chemical company，a multi-grade raw material supplier for medicine, food and cosmetics. We sell HA, PGA, Recombinant collagen, EGT, Ceramides, Ectoine. ect. 
Dr. Zhu Xiqiang，the CEO of Fengjin Beauty Biotech is the first scientist in the world to discover that polyglutamic acid has a whitening mechanism. After several years of in-depth research on polyglutamic acid, several derivative raw materials have been developed for this ingredient. At the same time, under the leadership of Dr. Zhu Xiqiang, its R&D team has also made major breakthroughs in the fermentation and extraction process of collagen and PDRN.
You're welcome to contact with us about pharma and raw materials.

Sorafenib tosylate can simultaneously inhibit a variety of kinases present in cells and on the cell surface, including RAF kinase, vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor receptor-3 (VEGFR -3), platelet-derived growth factor receptor-β (PDGFR-β), KIT and FLT-3. It can be seen that sorafenib tosylate has dual anti-tumor effects. On the one hand, it can directly inhibit tumor growth by inhibiting the RAF/MEK/ERK signaling pathway; on the other hand, it can inhibit VEGFR and PDGFR blocks the formation of tumor new blood vessels and indirectly inhibits the growth of tumor cells. Sorafenib tosylate is the most effective systemically administered drug to date for the treatment of progressive liver cancer and will likely become the new standard drug for the treatment of this disease.

Application

Sorafenib was originally discovered during biochemical analysis of structure-activity evaluation of inhibitor leads of c-RAF kinase. Sorafenib has a potent inhibitory effect on c-RAF, wild-type and mutant b-RAF, and can inhibit the serine/threonine kinase activity of c-RAF and b-RAF. Sorafenib can also inhibit the tyrosine kinase activity of human VEGFR-2, mouse VEGFR-2, VEGFR-3, PChemicalbookDGFR-β, FLT3 and c-KIT. The dual anti-tumor effect of sorafenib is achieved by inhibiting the activity of the above-mentioned kinases. Once-daily oral administration of sorafenib has demonstrated broad antitumor activity in animal transplant models of human tumors, including colon cancer, non-small cell carcinoma, breast cancer, melanoma, pancreatic cancer, leukemia and ovarian cancer, and mouse kidney cells Cancer model, RENCA model.